Trials / Completed
CompletedNCT01451645
Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 82 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if once-daily treatment with colchicine, compared to placebo, is effective in preventing gout flares in patients who are initiating therapy with allopurinol.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Colchicine (Colcrys®) | daily 0.6 mg colchicine dosing for 16 weeks |
| DRUG | placebo | daily placebo dosing for 16 weeks |
| DRUG | allopurinol | background therapy |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2012-08-01
- Completion
- 2012-09-01
- First posted
- 2011-10-14
- Last updated
- 2014-05-12
- Results posted
- 2014-05-12
Locations
37 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01451645. Inclusion in this directory is not an endorsement.